105 related articles for article (PubMed ID: 30683712)
1. Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7).
Henderson DJP; Houslay MD; Bangma CH; Hoffmann R
Clin Sci (Lond); 2019 Jan; 133(2):269-286. PubMed ID: 30683712
[TBL] [Abstract][Full Text] [Related]
2. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
3. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Böttcher R; Henderson DJ; Dulla K; van Strijp D; Waanders LF; Tevz G; Lehman ML; Merkle D; van Leenders GJ; Baillie GS; Jenster G; Houslay MD; Hoffmann R
Br J Cancer; 2015 Nov; 113(10):1502-11. PubMed ID: 26575822
[TBL] [Abstract][Full Text] [Related]
4. The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.
Henderson DJ; Byrne A; Dulla K; Jenster G; Hoffmann R; Baillie GS; Houslay MD
Br J Cancer; 2014 Mar; 110(5):1278-87. PubMed ID: 24518597
[TBL] [Abstract][Full Text] [Related]
5. cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
Gulliver C; Busiau T; Byrne A; Findlay JE; Hoffmann R; Baillie GS
Mol Oncol; 2024 Mar; 18(3):707-725. PubMed ID: 38126155
[TBL] [Abstract][Full Text] [Related]
6. Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Böttcher R; Dulla K; van Strijp D; Dits N; Verhoef EI; Baillie GS; van Leenders GJ; Houslay MD; Jenster G; Hoffmann R
Oncotarget; 2016 Oct; 7(43):70669-70684. PubMed ID: 27683107
[TBL] [Abstract][Full Text] [Related]
7. The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
van Strijp D; de Witz C; Heitkötter B; Huss S; Bögemann M; Baillie GS; Houslay MD; Bangma C; Semjonow A; Hoffmann R
Prostate Cancer; 2019; 2019():8107807. PubMed ID: 31275657
[TBL] [Abstract][Full Text] [Related]
8. The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus.
Byrne AM; Elliott C; Hoffmann R; Baillie GS
FEBS Lett; 2015 Mar; 589(6):750-5. PubMed ID: 25680530
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
van Strijp D; de Witz C; Vos PC; den Biezen-Timmermans E; van Brussel A; Wrobel J; Baillie GS; Tennstedt P; Schlomm T; Heitkötter B; Huss S; Bögemann M; Houslay MD; Bangma C; Semjonow A; Hoffmann R
Prostate Cancer; 2018; 2018():5821616. PubMed ID: 30147955
[No Abstract] [Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
11. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
[TBL] [Abstract][Full Text] [Related]
12. The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes.
Gulliver C; Huss S; Semjonow A; Baillie GS; Hoffmann R
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612262
[TBL] [Abstract][Full Text] [Related]
13. Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.
Gulliver C; Huss S; Semjonow A; Baillie GS; Hoffmann R
Br J Cancer; 2023 Oct; 129(9):1462-1476. PubMed ID: 37740039
[TBL] [Abstract][Full Text] [Related]
14. Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region.
Gulliver C; Baillie GS; Hoffmann R
Future Sci OA; 2023 Oct; 9(9):FSO888. PubMed ID: 37752916
[TBL] [Abstract][Full Text] [Related]
15. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
16. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
17. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
19. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
